More News! 11 Oct 2022
First patient dosed in study of idiopathic pulmonary fibrosis
Redx, a clinical-stage biotech company, is trialing RXC007, a wholly owned rho associated coiled-coil containing protein kinase 2 (ROCK2) selective inhibitor as a potential treatment for patients with idiopathic pulmonary…